Trial · NCT01447628
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 32
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Exercise Capacity - Endurance | 12 Weeks post study treatment | Time measured in seconds from start to end of the endurance bicycle cardiopulmonary exercise testing at 80% of the peak work rate. Peak work rate is determined by that achieved at the baseline incremental cardiopulmonary exercise test (CPET). Note that this was the primary end-point of the European study. Endurance CPET was not done in China. |
| Primary | Change in Resting Pulmonary Vascular Resistance (PVR) | 12 weeks post study treatment | To be measured by cardiac catheterisation in wood units. |
| Secondary | Oxygen Consumption (VO2) Level at Peak 12 Weeks After Study Treatment | 12 weeks post study treatment | Level of VO2 at peak measured during incremental cardio-pulmonary exercise testing |
| Secondary | Oxygen Consumption (VO2) at Metabolic Threshold | 12 weeks post study treatment | Level of VO2 at metabolic threshold measured during incremental cardio-pulmonary exercise test |
| Secondary | Ventilation / Volume of Exhaled Carbon Dioxide (VE/VCO2 Slope) | 12 weeks post study treatment | VE/VCO2 slope measured during incremental cardio-pulmonary exercise testing |
| Secondary | Oxygen Consumption (VO2) / Work Rate (WR) Slope | 12 weeks post study treatment | Level of VO2 / WR Slope measured during incremental cardio-pulmonary exercise testing |
| Secondary | Peak Oxygen (O2) Pulse Rate | 12 weeks post study treatment | O2 pulse rate (amount of oxygen consumed per heart beat) at peak measured during incremental cardio-pulmonary exercise test |
| Secondary | Oxygen Consumption (VO2) at the End of Endurance Cardio-pulmonary Exercise Test (CPET) | 12 weeks post study treatment | Level of VO2 measured at end of endurance cardio-pulmonary exercise test. Note that endurance CPET was not done in China, so this is reported only for the European dataset. |
| Secondary | Oxygen Consumption (VO2) at 3 Minutes | 12 weeks post study treatment | Level of VO2 measured at 3 minutes into endurance cardio-pulmonary exercise test (CPET) Note that endurance CPET was not done in China, hence results are presented only for the European dataset. |
| Secondary | Iron Indices: Serum Iron | 12 weeks post study treatment | Measurement of serum iron |
| Secondary | Iron Indices: Transferrin Saturations | 12 weeks post study treatment | Measurement of serum transferrin saturations. The saturation measures the iron concentration as a proportion of the iron binding capacity of transferrin. |
| Secondary | Iron Indices: Ferritin | 12 weeks post study treatment | Measured level of serum ferritin |
| Secondary | Iron Indices: Soluble Transferrin Receptors (sTfR) | 12 weeks post study treatment | Measure of serum sTfR level. Note that this was not measured in China, hence is reported only for the European dataset. |
| Secondary | 6 Minute Walk Test: Distance Walked | 12 weeks post study treatment | Distance in metres walked during standardised and validated 6 minute walk test |
| Secondary | 6 Minute Walk Test: Borg Dyspnoea Score After Test | 12 weeks post study treatment | Participant reported score on the modified Borg Dyspnoea scale (0-10) following 6 minute walk test. Higher scores indicate worsened dyspnoea. |
| Secondary | Iron Indices: N-terminal Pro B-type Natriuretic Peptide (NT-pro-BNP) | 12 weeks post study treatment | Measured level of NT-pro-BNP in blood sample. Note that this was not measured in China, hence is presented only for the European dataset. |
| Secondary | Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR Questionnaire): Symptom Score | 12 weeks post study treatment | Participant self reported symptom score using the CAMPHOR questionnaire (0-25). Scores for symptoms range from 0-25, with higher scores indicating worse symptoms. Note that this was not measured in China, hence is presented only for the European dataset. |
| Secondary | Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR Questionnaire): Activity Score | 12 weeks post study treatment | Participants' self reported score of their own level of activity based on the CAMPHOR questionnaire. Activity scores range from 0-30, with higher scores indicating more physical limitations Note that this was not measured in China, hence is presented only for the European dataset. |
| Secondary | Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR Questionnaire): QoL Score | 12 weeks post study treatment | Quality of Life score based on the Cambridge Pulmonary Hypertension Outcomes Review (CAMPHOR) questionnaire (0-25). Scores for QoL range from 0-25, with higher scores indicating worse quality of life Note that this was not measured in China, hence is presented only for the European dataset. |
| Secondary | Mean Right Atrial Pressure (Cardiac Catheter) | 12 weeks post study treatment | Mean right atrial pressure at rest measured by cardiac catheter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01447628/registered